The relationship between age and the effect of adjuvant therapies in women with primary breast cancer.
AffiliationDepartment of Medical Oncology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractApparent differences in the effectiveness of adjuvant therapies according to age, has led to controversy concerning the optimum treatment for women with breast cancer above and below 50 years of age. The data upon which this controversy is based and the possible reasons why chemotherapy appears more active in young women, whilst endocrine therapy appears more active in older women, is examined.
CitationThe relationship between age and the effect of adjuvant therapies in women with primary breast cancer. 1989, 32 Suppl 1:231-7 Horm Res
- Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
- Authors: Chlebowski RT, Haque R, Hedlin H, Col N, Paskett E, Manson JE, Kubo JT, Johnson KC, Wactawski-Wende J, Pan K, Anderson G
- Issue date: 2015 Dec
- The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women.
- Authors: Muss HB
- Issue date: 1994 Oct 1
- Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
- Authors: Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thürlimann B, Price KN, Coates AS, Hürny C, Bernhard J, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Goldhirsch A
- Issue date: 2000 Apr